Vonoprazan Fumarate is a novel potassium-competitive acid blocker (P-CAB) widely used for the treatment of gastroesophageal reflux disease, peptic ulcer, and Helicobacter pylori infection due to its rapid and long-lasting acid suppression activity.The present study aimed to formulate and evaluate chewable tablets of Vonoprazan Fumarate for improved patient compliance and ease of administration. The tablets were prepared by direct compression using suitable excipients, sweeteners, and superdisintegrants. Pre-compression and post-compression parameters were evaluated, including hardness, friability, weight variation, disintegration time, and drug release. The optimized formulation showed satisfactory tablet properties, rapid drug release, good stability, and acceptable palatability. The study concluded that Vonoprazan Fumarate chewable tablets are a promising dosage form for the treatment of acid-related disorders.
M.Patil et al. (Mon,) studied this question.